Economic burden of disease progression among multiple myeloma patients who have received transplant and at least one line of therapy in the US

Abstract Effects of disease progression on healthcare resource utilization (HRU) and costs among multiple myeloma (MM) patients with ≥1 line of therapy (LOT) who received their first stem cell transplant (SCT) within 1 year of initial MM diagnosis were estimated using a large US claims database. Dis...

Full description

Bibliographic Details
Main Authors: Rafael Fonseca, May Hagiwara, Sumeet Panjabi, Emre Yucel, Jacqueline Buchanan, Thomas Delea
Format: Article
Language:English
Published: Nature Publishing Group 2021-02-01
Series:Blood Cancer Journal
Online Access:https://doi.org/10.1038/s41408-021-00431-5